Aricept News and Research RSS Feed - Aricept News and Research

The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil (Aricept) reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity. This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases. Donepezil (Aricept) is the most prescribed Alzheimer's disease therapy worldwide.
TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai Inc.'s Aricept 23mg. [More]
Investigational drug focuses on slowing Alzheimer's disease progression

Investigational drug focuses on slowing Alzheimer's disease progression

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just that. [More]
Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401. [More]
Research findings may pave way to new treatment for Alzheimer's disease in humans

Research findings may pave way to new treatment for Alzheimer's disease in humans

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. [More]

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73. [More]
Scientists demonstrate new approach for quickly assembling drug-like compounds

Scientists demonstrate new approach for quickly assembling drug-like compounds

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment. [More]
Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS). [More]
ASS234 molecule inhibits aggregation of the Alzheimer's protein

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease. [More]
TPU, Eisai amend Aricept patch licensing agreement

TPU, Eisai amend Aricept patch licensing agreement

Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku Co., Ltd., pertaining to exclusive overseas marketing rights for the Aricept patch (once weekly donepezil HCl transdermal system). [More]
Patients with advanced Alzheimer’s benefit from drugs: Study finds

Patients with advanced Alzheimer’s benefit from drugs: Study finds

According to new developments patients with advanced Alzheimer’s disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated. [More]
Pfizer and Medivation drop further testing of failed Alzheimer’s drug

Pfizer and Medivation drop further testing of failed Alzheimer’s drug

A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors. [More]
Nicotine patch may help those with mild dementia

Nicotine patch may help those with mild dementia

The nicotine patch designed to help people quit smoking can also improve memory in older adults with mild cognitive impairment, or MCI, a small clinical trial found. [More]
New drug candidate may halt mental decline of Alzheimer's

New drug candidate may halt mental decline of Alzheimer's

A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published today in PLoS one. [More]
Dementia needs early diagnosis: Report

Dementia needs early diagnosis: Report

According to a new report sponsored by Alzheimer’s Disease International, nearly three-quarters of the 36 million people living with dementia have not been diagnosed with it. Experts say the lack of diagnosis has enormous repercussions on early treatment and care, and has a direct impact on the disease’s cost to society. [More]
Simple universal test to detect Alzheimer’s early

Simple universal test to detect Alzheimer’s early

A ten-minute memory test that gives early warning of Alzheimer’s in people as young as 50 is being piloted in GP surgeries. Using a touch-screen computer or an iPad, it can distinguish between normal forgetfulness and the more dangerous memory lapses that signal dementia in its earliest stages. If trials are successful, it could be in widespread use in under a year. The developer, Cambridge Cognition, said the mobile electronic test will allow GPs to access patients presenting memory problems more quickly, simply and accurately than with tradition paper-based tests. [More]
Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax. [More]
FDA approves Mylan's ANDA for Donepezil HCl Tablets to treat dementia linked with Alzheimer's

FDA approves Mylan's ANDA for Donepezil HCl Tablets to treat dementia linked with Alzheimer's

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease. [More]
Dr. Reddy’s launches generic ARICEPT, EFFEXOR XR and FEMARA in the US

Dr. Reddy’s launches generic ARICEPT, EFFEXOR XR and FEMARA in the US

Dr. Reddy's Laboratories today announced that it has launched three products in the US market. [More]
Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application to market a generic version of Eisai's Alzheimer's treatment Aricept Tablets, 5 mg and 10 mg. Shipment of this product has commenced. [More]
Eisai receives FDA Complete Response Letter for Aricept Patch NDA

Eisai receives FDA Complete Response Letter for Aricept Patch NDA

Eisai announced today that the United States Food and Drug Administration issued a Complete Response Letter to Teikoku Pharma USA, Inc., regarding the New Drug Application of the Aricept® Patch. [More]